Phase 2 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have signed a written consent form before any study procedures begin (or whose legal representative has signed on their behalf)
- People who have a solid tumour that has been confirmed by lab testing, is locally advanced or has spread to other parts of the body, and carries a specific genetic change called a KRAS p.G12C mutation, and whose cancer has not responded to standard treatments, has no standard treatment available, or who cannot tolerate standard treatment
- People with a life expectancy of at least 3 months
- People who have at least one tumour that can be measured on imaging scans, according to standard criteria (called RECIST v1.1)
- People who are in relatively good general health, rated 0 or 1 on a standard activity scale used in cancer research (ECOG performance status)
- People whose organ function results (such as blood tests) meet the levels required by the study at the screening stage
- People who are able to swallow tablets or capsules and do not have a digestive condition that would significantly affect how the body absorbs the medication
Who may not be able to join:
- People who have had another type of cancer within the past 3 years, or who currently have one, unless it was a fully treated early-stage cancer such as cervical carcinoma in situ, ductal carcinoma in situ of the breast, prostatic intraepithelial neoplasia, superficial non-invasive bladder cancer, or stage I skin cancer (not melanoma) — people who have been cancer-free for more than 3 years with no signs of return may still be considered (confirm with trial site)
- People who have had a serious allergic reaction to the study drug or its ingredients (such as microcrystalline cellulose)
- People who currently have, or have had within the past 6 months, a severe autoimmune disease — including serious immune-related reactions from previous cancer immunotherapy — or who need long-term steroid treatment at higher than low doses to manage an autoimmune condition
- People who test positive for HIV, hepatitis B, or hepatitis C
- People who have had, within the past 6 months, or currently have, a heart attack, unstable chest pain (angina), or a stroke
- People with significantly reduced heart function or a clinically significant heart condition
- People who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Wang Wang Jie M.D., Peking University Cancer Hospital & Institute
Phone: 021-80423288
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
recommended phase-2 dose (RP2D).; Number of participants with dose limiting toxicities
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.